Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study-Reference-Cited by-同舟云学术

Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study

Published:2021-09-01 Issue:3 Volume:10 Page:
ISSN:2045-0907
Container-title:CNS Oncology
language:en
Short-container-title:CNS Oncology

Author:

Annavarapu Srinivas¹^ORCID,Gogate Anagha²,Pham Trang³,Davies Kalatu³,Singh Prianka²,Robert Nicholas¹

Affiliation:

1. Ontada, Irving, TX 75039, USA

2. Bristol Myers Squibb, Lawrenceville, NJ 08648, USA

3. McKesson Specialty Health, The Woodlands, TX 77380, USA

Abstract

Aim: Investigate real-world outcomes and healthcare utilization of patients with glioblastoma multiforme (GBM) related to O6-methylguanine DNA methyltransferase (MGMT) promoter testing and methylation. Patients & methods: US Oncology Network data were analyzed for patients receiving first-line (1L) treatment for GBM. Results: Most patients received 1L radiation with temozolomide. Unadjusted median overall survival (OS) was higher in tested versus untested (median:18.1 vs 11.8 months) and in methylated versus unmethylated (median: 25.5 vs 12.4 months). Untested status, unmethylated MGMT and older age were associated with reduced OS and longer 1L treatment with increased OS. Similar findings were observed for progression-free survival. Utilization was similar between cohorts. Conclusion: In community oncology practices, MGMT methylation and testing were predictive of better survival in GBM.

Funder

Bristol-Myers Squibb

Publisher

Future Medicine Ltd

Subject

General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cns-2021-0007

Reference25 articles.

1. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016

2. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014

3. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis

4. NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers Version 5.2020. (2021). https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf

5. Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of renin angiotensin system inhibitors and metformin in Glioblastoma Therapy: a review;Cancer Chemotherapy and Pharmacology;2024-06-25

2. Extraction of Unstructured Electronic Health Records to Evaluate Glioblastoma Treatment Patterns;JCO Clinical Cancer Informatics;2024-06

3. Principles in the Management of Glioblastoma;Genes;2024-04-17

4. Intraoperative Magnetic Resonance Imaging (MRI)-Guided Resection of Glioblastoma: A Meta-Analysis of 1,847 Patients;World Neurosurgery;2023-12

5. Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM;Clinical Cancer Research;2023-09-29